Although SERMs are primarily used to prevent or treat osteoporosis, they have shown to be effective in HHT compensating partially, the haploinsufficiency present in HHT patients by increasing the protein levels of endoglin and ALK1. This evidence concerns the gene ACVRL1 and hereditary hemorrhagic telangiectasia.